Phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumours (EORTC 16041)

被引：0
|
作者：
Van Herpen, C.
Fiedler, W.
Toma, S.
Marreaud, S.
Van Laarhoven, H.
Lasch, P.
Bogaerts, J.
Heerschap, A.
Bordignon, C.
Punt, C.
机构：
[1] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[2] Univ Hosp Hamburg Eppendorf, Dept Med 2, Hamburg, Germany
[3] Molmed, Milan, Italy
[4] EORTC, Brussels, Belgium
[5] Radboud Univ Nijmegen Med Ctr, Dept Radiol, Nijmegen, Netherlands
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70371-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [31] Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors.
    Simonelli, M.
    Santoro, A.
    Zucali, P. A.
    Rimassa, L.
    De Vincenzo, F.
    Pressiani, T.
    Tronconi, M. C.
    Carnaghi, C.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Vascular effects of the vascular targeting agent NGR-hTNF in patients (pts) with advanced solid cancer: A dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) EORTC study.
    Van Laarhoven, H.
    Desar, I.
    Asten, J.
    Fiedler, W. M.
    Marreaud, S.
    Timmer-Bonte, J. N.
    Teroert, E.
    Bordignon, C.
    Heerschap, A.
    Van Herpen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas
    Mita, A. C.
    Yee, L. K.
    Papadopoulos, K. P.
    Heath, E. I.
    Romero, O.
    Lloyd, G. K.
    Cropp, G.
    Spear, M. A.
    Mita, M. M.
    LoRusso, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors
    Oh, Do-Youn
    Kim, Tae-Min
    Han, Sae-Won
    Shin, Dong-Yeop
    Lee, Yun Gyoo
    Lee, Keun-Wook
    Kim, Jee Hyun
    Kim, Tae-You
    Jang, In-Jin
    Lee, Jong-Seok
    Bang, Yung-Jue
    CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 28 - 36
  • [35] The novel direct-acting vascular targeting agent NGR-TNF exerts in vivo antitumor activity by inducing endothelial and tumor cell death in the absence of proangiogenic bone-marrow derived cell recruitment
    Di Matteo, Paola
    Hack, Christina
    Jedeszko, Christopher
    Porcellini, Simona
    Valentinis, Barbara
    Bordignon, Claudio
    Traversari, Catia
    Kerbel, Robert S.
    Rizzardi, Gian-Paolo
    CANCER RESEARCH, 2012, 72
  • [36] Pharmacokinetics of the intravenous administration of rViscumin in patients with solid tumours -: First results from EORTC Phase I Study 16002
    Schöffski, P
    Campone, M
    Riggert, S
    Mali, S
    Govaerts, AS
    Wilhelm-Ogunbiyi, K
    Langer, M
    Fumoleau, P
    Twelves, C
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S154 - S154
  • [37] Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors
    Beerepoot, LV
    Radema, SA
    Witteveen, EO
    Thomas, T
    Wheeler, C
    Kempin, S
    Voest, EE
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (10) : 1491 - 1498
  • [38] Phase I study of three-times daily oral etoposide in patients with refractory solid tumours
    Schwartsmann, G
    Caldas, APF
    Dalla Costa, T
    Di Leone, L
    Campos, O
    Cancela, A
    Schunemann, H
    Ferreira, AF
    Sander, E
    Mans, DRA
    CLINICAL DRUG INVESTIGATION, 2000, 19 (05) : 375 - 383
  • [39] Phase I Study of Three-Times Daily Oral Etoposide in Patients with Refractory Solid Tumours
    G. Schwartsmann
    A. P. F. Caldas
    T. Dalla Costa
    L. Di Leone
    O. Campos Junior
    A. Cancela
    H. Schunemann
    A. F. Ferreira Filho
    E. Sander
    D. R. A. Mans
    Clinical Drug Investigation, 2000, 19 : 375 - 383
  • [40] Phase I study of CYT997, a novel cytotoxic and vascular disrupting agent, given as a 24-hour intravenous infusion to patients with advanced solid tumours
    Lickliter, J.
    Smith, G.
    Burge, M.
    Coulthard, A.
    Wyld, D.
    Wilks, A.
    Vasey, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345